9 Apr 2024 • In ACS patients who stayed event-free on dual antiplatelet therapy for one month post-PCI, discontinuing aspirin & maintaining ticagrelor monotherapy after the initial dual therapy showed a clear advantage.

Dropping aspirin and continuing ticagrelor as soon as 1 month after PCI for ACS patients is as effective as continuing dual antiplatelet therapy (DAPT) over a longer period, but also is associated with less clinically-relevant and major bleeding, according to the ULTIMATE-DAPT placebo-controlled trial.

Along with the results from previous studies, these findings show that most patients in this population can benefit from superior clinical outcomes with aspirin discontinuation and maintenance on ticagrelor monotherapy after 1 month of dual antiplatelet therapy.

Source: The Lancet | Read full story